Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Oct. 31, 2025	Oct. 31, 2024
Cash flows from operating activities:
Net income (loss)	$ (15,778,071)	$ 21,951,795
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on related party investment – QCLS	(2,089,000)	(21,395,734)
Adjustment from accrued liabilities to warrant liabilities	(469,000)	0
Issuance costs – Series C preferred stock and warrants	1,234,553	0
Loss on issuance of Series C preferred stock	215,000	0
Gain on re-fair value of warrants	(106,000)	0
Stock-based compensation	120,984	341,832
Unrealized loss on marketable equity securities	165,126	0
Change in fair value of warrant liabilities	10,231,000	(3,913,000)
Change in fair value of derivative liability	(302,000)	(2,184,000)
Change in fair value of convertible note receivable - Femasys	(1,304,000)	(680,000)
Change in fair value of warrant asset – Femasys	1,941,000	1,234,000
Change in fair value of investment – QCLS	5,210,000	3,540,734
Change in fair value of warrants - QCLS	(1,218,000)	0
Change in assets and liabilities:
Increase in prepaid expenses and other current assets	(279,388)	(233,413)
Increase (decrease) in accounts payable	535,716	(40,775)
Decrease in accrued expenses	(1,081,424)	(49,471)
Net cash and cash equivalents used in operating activities	(2,973,504)	(1,428,032)
Cash flows from investing activities:
Investment in preferred stock and warrants	(3,000,000)	(7,000,000)
Net cash and cash equivalents used in investing activities	(3,000,000)	(7,000,000)
Cash flows from financing activities:
Repurchase of common stock, net	0	(2,145,708)
Redemption of preferred stock	0	(18,766,416)
Net proceeds from issuance of Series C convertible preferred stock	6,268,866	0
Accrued Series C convertible preferred stock and dividends	(61,250)	0
Net cash and cash equivalents used in financing activities	6,207,616	(20,912,124)
Effect of currency rate exchange on cash and cash equivalents	(258)	244
Net increase (decrease) in cash and cash equivalents	233,854	(29,339,912)
Cash and cash equivalents at beginning of the period	15,172,163	50,179,968
Cash and cash equivalents at end of the period	15,406,017	20,840,056
Supplemental disclosure of non-cash investing and financing activities:
Reclassification of Series B Convertible Preferred Stock and dividends to current liability	0	16,190,179
Accretion of discounts to redemption value of Series B Preferred Stock	0	3,193,404
Accrual of Series C Convertible Preferred Stock dividends	96,639	0
Accrual of Series C Convertible Preferred Stock issuance costs	86,419	0
Accretion of discounts to redemption value of Series C Preferred Stock	901,996	0
Initial fair value of investment in QCLS Series H preferred shares	3,483,000	0
Initial fair value of investment in QCLS Series H warrants	1,606,000	0
Non-cash derivative liability at initial fair value	1,995,000	0
Non-cash warrant liability at initial fair value	5,220,000	0
Fair value of contingently redeemable placement agent warrants	417,000	0
Excise tax accrued on repurchase of common stock	$ 0	$ 21,457